Literature DB >> 23467704

The expression and function of Toll-like receptors 3 and 9 in human colon carcinoma.

Keiichiro Nojiri1, Kazushi Sugimoto, Katsuya Shiraki, Masahiko Tameda, Yuuji Inagaki, Satoko Kusagawa, Suguru Ogura, Junichiro Tanaka, Misao Yoneda, Norihiko Yamamoto, Hiroshi Okano, Yoshiyuki Takei, Masaaki Ito, Chika Kasai, Hidekazu Inoue, Koujiro Takase.   

Abstract

Toll-like receptors (TLRs) are pattern-recognition receptors that are important in immune signaling. TLR recognition of various viral components including double-stranded RNA (TLR3) and unmethylated CpG-DNA (TLR9) plays a crucial role in cell survival. However, TLR expression and function in colon carcinoma cells are not well clarified. We investigated the expression of TLR3 and TLR9 in colon carcinoma cells using immunohistochemical methods. The function of TLR3 and TLR9 signaling in carcinoma cell lines was studied by direct cell stimulation with, or by cell transfection of, polyinosinic-polycytidylic acid (Poly I:C), a synthetic form of dsRNA, and by cell stimulation with CpG-oligodeoxynucleotides (ODNs), respectively. Positive TLR3 and TLR9 immunohistochemical staining was observed in 91 and 86% of human hepatocellular carcinoma (HCC) tissues, respectively. Cell surface stimulation of TLR3 with Poly I:C did not affect cell viability but it did activate NF-κB activity. By contrast, stimulation of intracellular TLRs with transfected Poly I:C significantly induced apoptosis. Cell surface stimulation of TLR9 with CpG-ODNs promoted cell proliferation, and, furthermore, these CpG-ODN TLR9 agonists reduced the cytotoxicity of the anticancer drug adriamycin. Cell surface expression of TLR3 and TLR9 in colon carcinoma cells plays an important role in cell survival. In addition, the proapoptotic activity of intracellularly expressed TLR3 may provide the possibility of using TLR3 agonists as novel clinical cytotoxic agents against colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467704     DOI: 10.3892/or.2013.2322

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Toll-like receptor 9 expression in the natural history of Barrett mucosa.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Heikki Takala; Kalervo Metsikkö; Petri Lehenkari; Juha Saarnio; Tuomo Karttunen
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

2.  Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer.

Authors:  Tatsuya Yoshida; Takuya Miura; Tomoh Matsumiya; Hidemi Yoshida; Hajime Morohashi; Yoshiyuki Sakamoto; Akira Kurose; Tadaatsu Imaizumi; Kenichi Hakamada
Journal:  Clin Exp Gastroenterol       Date:  2020-10-02

Review 3.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

4.  Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.

Authors:  Lovisa Farnebo; Arash Shahangian; Yunqin Lee; June Ho Shin; Ferenc A Scheeren; John B Sunwoo
Journal:  Oncotarget       Date:  2015-04-30

5.  Combinatorial treatment with polyI:C and anti-IL6 enhances apoptosis and suppresses metastasis of lung cancer cells.

Authors:  Wai Hoe Lau; Xiphias Ge Zhu; Shamaine Wei Ting Ho; Shu Chun Chang; Jeak Ling Ding
Journal:  Oncotarget       Date:  2017-05-16

Review 6.  Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.

Authors:  Fernando Torres Andón; Sergio Leon; Aldo Ummarino; Esther Redin; Paola Allavena; Diego Serrano; Clément Anfray; Alfonso Calvo
Journal:  Biomedicines       Date:  2022-07-04

7.  The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Tuula Salo; Katja Porvari; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

8.  Epistatic effect of TLR3 and cGAS-STING-IKKε-TBK1-IFN signaling variants on colorectal cancer risk.

Authors:  Calogerina Catalano; Miguel Inacio da Silva Filho; Christoph Frank; Shun Lu; Katerina Jiraskova; Veronika Vymetalkova; Miroslav Levy; Vaclav Liska; Ondrej Vycital; Alessio Naccarati; Ludmila Vodickova; Kari Hemminki; Pavel Vodicka; Alexander N R Weber; Asta Försti
Journal:  Cancer Med       Date:  2019-12-23       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.